SeekingAlphaAugust 28, 2026 at 1:10 AM NY7 days ago

INmune Bio: CORDStrom In The Lead After Signs Of UK Regulatory Alignment

INmune Bio is significantly undervalued, with Ebstrocel for RDEB driving a compelling investment thesis. Read more on INMB stock here.

Read the Full Story at the Source

The summary here comes from the news provider; the rest of the article lives on the publisher's site — SeekingAlpha

Companies in This Story